Patent · US Active

Use of ADCC-optimized antibodies for treating weak patients

US8501171B2 · kind B2 · utility

6Cited by

1References

10Claims

0Family size

Assignee

Laboratoire Francais du Fractionnement et des Biotechnologies · FR

Inventors

Dominique Bourel · La Madeleine, FR
Sylvie Jorieux · Lomme, FR
Christophe De Romeuf · Lille, FR
Philippe Klein · Alès, FR
Christine Gaucher · Haubourdin, FR
Nicolas Bihoreau · Orsay, FR
Emmanuel Nony · Antony, FR

Key dates

Filing date	Mar 23, 2010
Grant date	Aug 6, 2013
Priority date	—
Expiry date	Jun 30, 2030

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.